extract: 2026-01-13-aon-glp1-employer-cost-savings-cancer-reduction

Pentagon-Agent: Epimetheus <968B2991-E2DF-4006-B962-F5B0A0CC8ACA>

domains/health/GLP-1 receptor agonists are the largest therapeutic category launch in pharmaceutical history but their chronic use model makes the net cost impact inflationary through 2035.md

@@ -83,6 +83,12 @@ Danish cohort achieved same weight loss outcomes (16.7% at 64 weeks) using HALF
 
 BALANCE Model's dual payment mechanism (capitation adjustment + reinsurance) plus manufacturer-funded lifestyle support represents the first major policy attempt to address the chronic-use cost structure. The Medicare GLP-1 Bridge (July 2026) provides immediate price relief while full model architecture is built, indicating urgency around cost containment.
 
+
+### Additional Evidence (challenge)
+*Source: [[2026-01-13-aon-glp1-employer-cost-savings-cancer-reduction]] | Added: 2026-03-18*
+
+Aon's 192K patient analysis shows medical costs grow only 2% for GLP-1 users after 12 months versus 6% for non-users, with diabetes patients showing 6-9 percentage points lower cost growth at 30 months depending on adherence. This suggests the 'inflationary through 2035' claim may be payment-model-dependent rather than universally true—capitated long-term risk-bearers may see net savings while FFS short-term payers see inflation.
+
 ---
 
 Relevant Notes:

domains/health/glp-1-persistence-drops-to-15-percent-at-two-years-for-non-diabetic-obesity-patients-undermining-chronic-use-economics.md

@@ -71,6 +71,12 @@ Digital behavioral support may partially solve the persistence problem: UK study
 
 BALANCE Model's manufacturer-funded lifestyle support requirement directly addresses the persistence problem by mandating evidence-based programs for GI side effects, nutrition, and physical activity—the factors most associated with discontinuation. This shifts the cost of adherence support from payers to manufacturers.
 
+
+### Additional Evidence (extend)
+*Source: [[2026-01-13-aon-glp1-employer-cost-savings-cancer-reduction]] | Added: 2026-03-18*
+
+Aon data shows adherence is the binding variable for cost-effectiveness: the 80%+ adherent cohort shows 9 percentage points lower cost growth for diabetes and 7 points lower for weight loss, versus 6 and 3 points for the overall population. This means the economic case requires not just persistence but high adherence, making the 15% two-year persistence rate even more problematic for chronic use economics.
+
 ---
 
 Relevant Notes:

domains/health/lower-income-patients-show-higher-glp-1-discontinuation-rates-suggesting-affordability-not-just-clinical-factors-drive-persistence.md

@@ -43,6 +43,12 @@ The source does not provide granular income-stratified discontinuation rates, so
 
 The Trump Administration deal establishes a $50/month out-of-pocket maximum for Medicare beneficiaries, explicitly targeting affordability as a persistence barrier. The $245/month Medicare price (down from ~$1,350) combined with the OOP cap is designed to address the affordability-driven discontinuation pattern observed in lower-income populations.
 
+
+### Additional Evidence (extend)
+*Source: [[2026-01-13-aon-glp1-employer-cost-savings-cancer-reduction]] | Added: 2026-03-18*
+
+Aon data shows the 80%+ adherent cohort captures dramatically stronger cost offsets (9 points for diabetes vs 6 for overall population), meaning affordability barriers that reduce adherence don't just affect clinical outcomes—they eliminate the economic case for coverage, creating a self-reinforcing cycle where cost concerns prevent the adherence needed to justify the cost.
+
 ---
 
 Relevant Notes:

domains/health/semaglutide-reduces-kidney-disease-progression-24-percent-and-delays-dialysis-creating-largest-per-patient-cost-savings.md

@@ -40,6 +40,12 @@ FLOW trial (N=3,533, median 3.4 years follow-up) showed 24% reduction in major k
 
 SELECT trial economic model shows $2,074 per-subject lifetime savings from avoided CKD, supporting the claim that kidney protection generates substantial cost savings. However, diabetes prevention ($14,431) generates even larger savings.
 
+
+### Additional Evidence (confirm)
+*Source: [[2026-01-13-aon-glp1-employer-cost-savings-cancer-reduction]] | Added: 2026-03-18*
+
+Aon's real-world claims data confirms the temporal pattern of GLP-1 cost offsets: medical cost growth is 6 percentage points lower at 30 months for diabetes patients, with the savings materializing after the first 12 months when costs initially rise 23% versus 10% for non-users. This validates the kidney protection findings in a large commercial population.
+
 ---
 
 Relevant Notes:

inbox/archive/.extraction-debug/2026-01-13-aon-glp1-employer-cost-savings-cancer-reduction.json

@@ -0,0 +1,32 @@
+{
+  "rejected_claims": [
+    {
+      "filename": "glp-1-cost-effectiveness-requires-long-term-risk-bearing-because-savings-lag-drug-costs-by-12-18-months.md",
+      "issues": [
+        "missing_attribution_extractor"
+      ]
+    },
+    {
+      "filename": "glp-1-receptor-agonists-show-50-percent-ovarian-cancer-reduction-and-14-percent-breast-cancer-reduction-in-women.md",
+      "issues": [
+        "missing_attribution_extractor"
+      ]
+    }
+  ],
+  "validation_stats": {
+    "total": 2,
+    "kept": 0,
+    "fixed": 2,
+    "rejected": 2,
+    "fixes_applied": [
+      "glp-1-cost-effectiveness-requires-long-term-risk-bearing-because-savings-lag-drug-costs-by-12-18-months.md:set_created:2026-03-18",
+      "glp-1-receptor-agonists-show-50-percent-ovarian-cancer-reduction-and-14-percent-breast-cancer-reduction-in-women.md:set_created:2026-03-18"
+    ],
+    "rejections": [
+      "glp-1-cost-effectiveness-requires-long-term-risk-bearing-because-savings-lag-drug-costs-by-12-18-months.md:missing_attribution_extractor",
+      "glp-1-receptor-agonists-show-50-percent-ovarian-cancer-reduction-and-14-percent-breast-cancer-reduction-in-women.md:missing_attribution_extractor"
+    ]
+  },
+  "model": "anthropic/claude-sonnet-4.5",
+  "date": "2026-03-18"
+}

inbox/archive/2026-01-13-aon-glp1-employer-cost-savings-cancer-reduction.md

@@ -7,9 +7,13 @@ date: 2026-01-13
 domain: health
 secondary_domains: [internet-finance]
 format: report
-status: unprocessed
+status: enrichment
 priority: high
 tags: [glp-1, employer-costs, cancer-risk, cardiovascular, cost-offset, real-world-evidence]
+processed_by: vida
+processed_date: 2026-03-18
+enrichments_applied: ["glp-1-persistence-drops-to-15-percent-at-two-years-for-non-diabetic-obesity-patients-undermining-chronic-use-economics.md", "semaglutide-reduces-kidney-disease-progression-24-percent-and-delays-dialysis-creating-largest-per-patient-cost-savings.md", "lower-income-patients-show-higher-glp-1-discontinuation-rates-suggesting-affordability-not-just-clinical-factors-drive-persistence.md", "GLP-1 receptor agonists are the largest therapeutic category launch in pharmaceutical history but their chronic use model makes the net cost impact inflationary through 2035.md"]
+extraction_model: "anthropic/claude-sonnet-4.5"
 ---
 
 ## Content
@@ -49,3 +53,12 @@ WHY ARCHIVED: The temporal cost dynamics (costs up Y1, down Y2+) are the most im
 EXTRACTION HINT: Focus on the temporal cost curve and what it implies for different payment models. The cancer finding is separately important but preliminary.
 
 flagged_for_rio: ["GLP-1 cost dynamics have direct implications for health investment thesis — long-term risk-bearers capture savings that short-term payers miss"]
+
+
+## Key Facts
+- Aon analyzed 192,000+ GLP-1 users in U.S. commercial health claims data
+- First 12 months on Wegovy/Zepbound: medical costs rise 23% vs 10% for non-users
+- After 12 months: medical costs grow 2% vs 6% for non-users
+- Female GLP-1 users: ~50% lower ovarian cancer incidence, 14% lower breast cancer incidence
+- Adherent users (80%+): 47% MACE reduction for women, 26% for men
+- Study released January 13, 2026